Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis and review of comparative clinical- and cost-effectiveness

Boudreau R, Blackhouse G, Goeree R, Mierzwinski-Urban M
Record ID 32008000100
English, French
Authors' objectives:

"Research questions 1. What is the comparative clinical benefit and long-term harm of adalimumab, alefacept, efalizumab, etanercept, and infliximab for the treatment of adult patients with severe plaque psoriasis? 2. What is the optimal dose of adalimumab, alefacept, efalizumab, etanercept, and infliximab for the treatment of adult patients with severe plaque psoriasis? 3. What is the comparative cost-effectiveness of adalimumab, alefacept, efalizumab, etanercept, and infliximab for the treatment of adult patients with severe plaque psoriasis? 4. What is the budget impact for funding treatment with adalimumab, alefacept, efalizumab, etanercept, or infliximab for one year for all Canadian adults with severe plaque psoriasis?" (executive summary)

Authors' methods: Systematic review
Details
Project Status: Completed
URL for project: http://cadth.ca/index.php/en/hta/reports-publications/search/
Year Published: 2007
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Antibodies, Monoclonal
  • Psoriasis
Contact
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.